Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US

Set Alert for US

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered. 

Advisory Committees Drug Review

Confronting The Challenges Of Marketing Cell And Gene Therapies

The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.

Europe North America

Potential For Califf’s Second US FDA Commissioner Term Surprises, Excites Stakeholders

Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.

FDA Leadership

Moderna's COVID-19 Vaccine Booster US FDA Panel Nod Driven By Pragmatism

Despite lack of enthusiasm with immunobridging study data, the panel endorsed emergency use in certain at-risk populations, in part because it would be hard to turn down the Moderna booster when an identical EUA had been issued for Pfizer/BioNTech's mRNA vaccine.

Coronavirus COVID-19 Vaccines

Strike Two: US FDA Vaccine Advisors Again Shoot Down Broad COVID-19 Vaccine Boosting

Surprising move to have VRBPAC debate offering mRNA boosters to everyone 18 and up, less than one month after the panel shot that down for Pfizer’s vaccine, thus stalling the White House’s plan for a broad booster rollout, was driven internally by the FDA, a senior health official said.

Coronavirus COVID-19 Vaccines

Pfizer’s ‘Industry First’ Warranty Program For Xalkori Available To Medicare Part D Patients

Pilot program offers Part D beneficiaries an alternative to manufacturer assistance in the form of copay coupons, which are prohibited in government-sponsored health plans. New program also available to commercial insurance and cash-paying patients.

Medicare Reimbursement

Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma

Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.

Politics Sales & Earnings

Janssen Booster Evidence Draws Questions From US FDA, But Also A Nod Towards Benefits

Agency assessors couldn’t independently verify several Janssen analyses of booster shot data and raised concerns about small samples sizes and an unvalidated immunogenicity assay.

Vaccines Advisory Committees

NIH Mix and Match Study Suggests mRNA COVID Vaccines May Offer Stronger Boost Than J&J

Though not designed to facilitate inter-group comparisons, a preprint study of heterologous and homologous boosting with the three US available COVID-19 vaccines indicate Johnson and Johnson primary vaccines may get greater protection from an mRNA booster.

United States Advisory Committees

J&J Offers Sliding Timeframe for Covid Boosters Based on Individual Patient and Geographic Need

Johnson and Johnson’s one-shot Covid vaccine gets a solid efficacy boost with second shot administered two months after primary vaccination, but the company will argue based on much more limited data that a longer window between shots may be preferable for some populations.  

Advisory Committees Coronavirus COVID-19

Moderna COVID-19 Vaccine: Booster Study Hits Only One Of Two Immunogenicity Endpoints

Immune responses to a single booster dose of mRNA-1273 would be considered successfully bridged to the two-dose primary series if each of two immunobridging criteria were met, but the mRNA vaccine missed the prespecified success criteria for seroresponse rate, the FDA said.

Advisory Committees Coronavirus COVID-19

US FDA’s Woodcock ‘Managing As If She’s Been Commissioner,’ Not Afraid To Act, CBER Director Says

Peter Marks says Acting Commissioner Janet Woodcock’s tenure running the FDA has been no different than if a permanent commissioner were in place.

FDA Leadership
See All
UsernamePublicRestriction

Register